Autopsy report · NCT02984085

Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB.

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Replaced by new study in progress”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 1 year 6 months before it stopped.
3 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1, Phase 2
Sponsor: Holostem s.r.l.
Sponsor type: Industry
Conditions: Recessive Dystrophic Epidermolysis Bullosa
Interventions: Genetically corrected cultured epidermal autograft (ATMP)
Participants: 3
Sites: 1
Countries: Austria

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.